| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1207281 |
| P698 | PubMed publication ID | 23363473 |
| P2093 | author name string | Berge A Minassian | |
| Jennifer J Rilstone | |||
| Reem A Alkhater | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| serotonin | Q167934 | ||
| brain dopamine-serotonin vesicular transport disease | Q55787757 | ||
| dopamine | Q170304 | ||
| P304 | page(s) | 543-50 | |
| P577 | publication date | 2013-02-07 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Brain dopamine-serotonin vesicular transport disease and its treatment | |
| P478 | volume | 368 |
| Q36232197 | A new knock-in mouse model of l-DOPA-responsive dystonia |
| Q64055801 | A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets |
| Q50553485 | Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. |
| Q26826093 | Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders |
| Q90414129 | Clinical and Genetic Heterogeneity in a Cohort of Chinese Children With Dopa-Responsive Dystonia |
| Q26852309 | Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders |
| Q33770716 | Clinical spectrum of dopa-responsive dystonia and related disorders |
| Q33627712 | DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously |
| Q36011221 | Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. |
| Q48326568 | Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles. |
| Q64119023 | Dominant mutation causes intellectual disability with remitting epilepsy |
| Q39000590 | Dopamine depleters in the treatment of hyperkinetic movement disorders |
| Q48531888 | Dopamine receptor agonist treatment for idiopathic dystonia: A reappraisal in humans and mice |
| Q27304699 | Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. |
| Q37171865 | Exome Sequencing and the Management of Neurometabolic Disorders. |
| Q55507401 | Expanding the Spectrum of Dopa-Responsive Dystonia (DRD) and Proposal for New Definition: DRD, DRD-plus, and DRD Look-alike. |
| Q64809057 | Eye movement disorders and neurological symptoms in late-onset inborn errors of metabolism |
| Q36775218 | Genes that Affect Brain Structure and Function Identified by Rare Variant Analyses of Mendelian Neurologic Disease |
| Q35810975 | Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity |
| Q33919548 | Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo |
| Q48301354 | Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum |
| Q39294770 | Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky |
| Q37591449 | Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease. |
| Q38926644 | Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease |
| Q59793271 | Modelling brain dopamine-serotonin vesicular transport disease in |
| Q38590771 | Monoamine neurotransmitter disorders--clinical advances and future perspectives. |
| Q37589110 | N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux |
| Q38655437 | NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment. |
| Q39144226 | Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment |
| Q38218281 | Parkinsonism and inborn errors of metabolism. |
| Q57175515 | Presynaptic disorders: a clinical and pathophysiological approach focused on the synaptic vesicle |
| Q38133704 | Rare-disease genetics in the era of next-generation sequencing: discovery to translation |
| Q36691830 | Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration |
| Q34673305 | Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease |
| Q33918224 | Simultaneous determination of all forms of biopterin and neopterin in cerebrospinal fluid |
| Q41776183 | Specialty grand challenge - genetic disorders |
| Q90264494 | Synaptic metabolism: a new approach to inborn errors of neurotransmission |
| Q37711589 | Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. |
| Q28822273 | The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders |
| Q38187316 | The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource |
| Q38178697 | Treatable inborn errors of metabolism causing neurological symptoms in adults |
| Q47146470 | Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients. |
| Q35775723 | VMAT2 and Parkinson's disease: harnessing the dopamine vesicle |
| Q41031814 | Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. |
| Q28385737 | Vesicular integrity in Parkinson's disease |
| Q38201694 | What is new for monoamine neurotransmitter disorders? |
| Q46776807 | What is the role of dopamine in childhood neurological disorders? |
| Q35042570 | Whole-exome analysis of foetal autopsy tissue reveals a frameshift mutation in OBSL1, consistent with a diagnosis of 3-M Syndrome |
| Q50297016 | loading of Serotonin in synaptic vesicles |
Search more.